Τόμος 34 (2016) – Τεύχος 2 – Άρθρο 6 – Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Ελληνική Έκδοση – Volume 34 (2016) – Issue 2 – Article 6 – Epitheorese Klinikes Farmakologias και Farmakokinetikes-Greek Edition

Παναγιώτα Καράτση¹, Ελένη Κίντζιου²

¹Αισθητικός Κοσμητολόγος MSc, ²Φαρμακοποιός, Καθηγήτρια Τμήματος Αισθητικής και Κοσμητολογίας, Σχολή Επαγγελμάτων Υγείας και Πρόνοιας, ΤΕΙ Αθήνας, Αγ. Σπυρίδωνος, GR-12243, Αιγάλεω, Ελλάς

Panagiota Karatsi¹, Eleni Kintziou²

¹Aesthetician Cosmetologist MSc, ²Pharmacist, Professor of Aesthetics and Cosmetology, School of Health and Caring Professions, Technological Educational Institution of Athens, Egaleo, Athens, Hellas

2. Malik V.S., Willett WC, Hu F.B.: Global obesity: Trends, risk factors and policy implications. Nat. Rev. Endocrinol. 9: 13-27 (2012)

3. Kopelman P.G.: Obesity as a medical problem. Nature 404: 635-643 (2000)

4. Wang Y.C., Mcpherson K., Marsh T., Gortmaker S.I., Brown M.: Health and economic burden of the projected obesity trends in the USA and the UK. Lancet 378: 815-825 (2011)

5. Baumer J.H.: Obesity and overweight: its prevention, identification, assessment and management. Arch. Dis. Child. Educ. Pract. Ed. 92(3): ep92‐6, 2007

6. Polikandrioti M., Stefanou E.V.: Obesity disease. Health Sci. J. 3(3): 2009

7. Khoo C.M., Liew C.F., Chew S.K., Tai E.S.: The impact of central obesity as a prerequisite for the diagnosis of metabolic syndrome. Obesity (Silver Spring) 15(1): 262‐269 (2007)

8. Al‐Lawati J.A., Jousilahti P.: Body mass index, waist circumference and waist‐to‐hip ratio cut‐off points for categorisation of obesity among Omani Arabs. Public Health Nutr. 11(1): 102‐108 (2008)

9. Bruch H.: Developmental considerations of anorexia nervosa and obesity. Can. J. Psychiatry 26(4): 212‐217 (1981)

10. Wisniewski A.B., Chernausek S.D.: Gender in childhood obesity: family environment, hormones, and genes. Gend. Med. 6(Suppl 1): 76‐85 (2009)

11. Oken E.: Maternal and child obesity: the causal link. Obstet. Gynecol. Clin. North Am. 36(2): 361‐377 (2009)

12. Atlantis E., Baker M.: Obesity effects on depression: systematic review of epidemiological studies. Int, J, Obes (Lond). 32(6): 881‐891 (2008)

13. Atlantis E., Ball K.: Association between weight perception and psychologicaldistress. Int. J. Obes. (Lond). 32(4): 715‐721 (2008)

14. Vaidya V.: Psychosocial aspects of obesity. Adv. Psychosom. Med. 27: 73‐85 (2006)

15. Drewnowski A.: Obesity, diets, and social inequalities. Nutr. Rev. 67(Suppl 1): S36‐39 (2009)

16. Darmon N., Drewnowski A.: Does social class predict diet quality? Am. J. Clin. Nutr. 87(5): 1107‐1117 (2008)

17. Drewnowski A., Specter S.E.: Poverty and obesity: the role of energy density and energy costs. Am. J. Clin. Nutr. 79(1): 6‐16 (2004)

18. Belahsen R., Rguibi M.: Population health and Mediterranean diet in southern Mediterranean countries. Public Health Nutr. 9: 1130-1135 (2006)

19. Trichopoulou A., Lagiou P.: Healthy traditional Mediterranean diet: an expression of culture, history and lifestyle. Nutr. Rev. 55: 383-389 (1997)

20. McElroy SL., Kotwal R., Malhotra S., Nelson EB., Keck PE., Nemeroff CB. Are mood disorders and obesity related? A review for the mental health professional. J. Clin. Psychiatry 65(5): 634‐651 (2004)

21. Keck P.E., McElroy S.L.: Bipolar disorder, obesity, and pharmacotherapy‐associated weight gain. J. Clin. Psychiatry 64(12): 1426‐1435 (2003)

22. Morris D.L., Rui L.: Recent advances in understanding leptin signaling and leptin resistance. Am. J. Physiol. Endocrinol. Metab. 297(6): E1247‐1259 (2009)

23. Speakman J.R.: Obesity: the integrated roles of environment and genetics. J. Nutr. 134(8 Suppl): 2090-2105 (2004)

24. Avenell A., Sattar N., Lean M.: ABC of obesity. Management: Part I‐‐behavior change, diet, and activity. BMJ 333(7571): 740‐743 (2006)

25. Cannon C.P., Kumar A.: Treatment of overweight and obesity: lifestyle, pharmacologic, and surgical options. Clin. Cornerstone 9(4): 55‐68 (2009)

26. Fleming J.W., Mcclendon K,S, Riche D.M.: New obesity agents: Lorcaserin and phentermine/topiramate. Ann. Pharmacother. 47: 1007-1016 (2013)

27. Smith S.R, Prosser W.A., Donahue D.J., Morgan M.E., Anderson C.M., Shanahan W.R. et al.: Lorcaserin (APD356), a selective 5-HT(2C) agonist, reduces body weight in obese men and women. Obesity (Silver Spring) 17: 494-503 (2009)

28. Smith S.R., Weissman N.J., Anderson C.M., Sanchez M., Chuang E., Stubbe S., et Al:. Multicenter, placebo-controlled trial of lorcaserin for weight management. N. Engl. J. Med. 363: 245-256 (2010)

29. O’neil P.M., Smith S.R., Weissman N.J., Fidler M.C., Sanchez M., Zhang J., et al.: Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: The BLOOM-DM study. Obesity (Silver Spring) 20: 1426-1436 (2012)

30. Fidler M.C., Sanchez M., Raether B., Weissman NJ., Smith S.R., Shan Ahan W.R.,et al.: A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: The BLOSSOM trial. J. Clin. Endocrinol. Metab. 96: 3067-3077 (2011)

31. Product information for Topamax (topiramate). Jansen Pharmaceuticals, Inc, Titusville, New Jersey, 2012

32. Richard D., Ferland J., Lalonde J., Samson P., Deshaies Y.: Influence of topiramate in the regulation of energy balance. Nutrition 16: 961-966 (2000)

33. Richard D., Picard F., Lemieux C., Lalonde J., Samson P., De Shaies Y.: The effects of topiramate and sex hormones on energy balance of male and female rats. Int. J. Obes. Relat. Metab. Disord. 26: 344-353 (2002)

34. Picard F., Deshaies Y., Lalonde J., Samson P., Richard D.: Topiramate reduces energy and fat gains in lean (Fa/?) and obese (fa/fa) Zucker rats. Obes. Res. 8: 656-663 (2000)

35. Vivus Inc. Vivus announces FDA approval of once daily QsymiaTM (phentermine and topiramate extended-release) capsules CIV. Available at: www.vivus.com

36. Allison D.B., Gadde K.M., Garvey W.T., Peterson C.A., Schwiers M.l., Najarian T., et al.: Controlled-release phentermine/topiramate in severely obese adults: A randomized controlled trial (EQUIP). Obesity (Silver Spring) 20: 330-342 (2012)

37. Gadde K.M., Allison D.B., Ryan D.H., Peterson C.A., Troupin B., Schwiers M.l., et al.: Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adultsm(CONQUER): A randomised, placebo-controlled, phase 3 trial. Lancet 377: 1341-1352 (2011)

38. Garvey W.T., Ryan D.H., Look M., Gadde K.M., Allison D.B., Peterson C.A., et al.: Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): A randomized, placebo controlled, phase 3 extension study. Am. J. Clin. Nutr. 95: 297-308 (2012)

39. Anonymous: Two drugs for weight loss. JAMA 312: 955-957 (2014)

40. Greenway F.l, Dunayevich E., Tollefson G., Erickson J., Guttadauria M., Fujioka K., et al.: Comparison of combined bupropion and naltrexone therapy for obesity with monother apy and placebo. J. Clin. Endocrinol. Metab. 94: 4898-4906 (2009)

41. Mcelroy S.l., Guerdjikova A.I., Rosen A., Kim D.D., Landbloom R., Dunayevich E.: An open-label study evaluating the naltrexone SR/bupropion SR combination therapy in overweight or obese subjects with major depression. American Diabetes Association. 70^th Scientific Meeting, 2010:1851-P (abstract)

42. Hollander P., Plodkowski R., Gupta A.K.: CORDiabetes: Naltrexone SR/bupropion SR combination therapy led to significant and sustained weight loss and improved HbA1c in overweight/ obese subjects with type 2 diabetes. American Diabetes Association, 70^th Scientific Meeting, 2010:56-OR (abstract)

43. Apovian C.M., Aronne L., Rubino D., Still C., Wyatt H., Burns C., et al.: A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity (Silver Spring) 21: 935-943 (2013)

44. Wadden T.A., Foreyt J.P., Foster G.D., Hill J.O., Klein S., O’neil P.M., et al.: Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: The COR-BMOD trial. Obesity (Silver Spring) 19: 110-120 (2011)

45. Tomkin G.H.: Treatment of type 2 diabetes, lifestyle, GLP1 agonists and DPP4 inhibitors. World J. Diabetes 5: 636-650 (2014)

46. Wadden T.A., Hollander P., Klein S., Niswender K., Woo V., Hale P.M., et al.: Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study. Int. J. Obes. (Lond), 2014; doi: 10.1038/ijo.2014.88

47. Defronzo R.A., Bergenstal R.M., Bode Β., Kushner R., Lewin Α.J., Skjoth T.V., et al.: Effects of liraglutide 3.0 mg and 1.8 mg on body weight and cardiometabolic risk factors in overweight and obese adults with type 2 diabetes mellitus (T2DM): The Scale diabetes randomized, double-blind, placebo-controlled, 56-week trial. ICE/ENDO, Abstract OP, 2014

48. Astrup A., Carraro R., Finer N., Harper A., Kunesova M., Lean M.E., et al. : Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int. J. Obes. (Lond) 36: 843-854 (2012)

49. Kim S.H., Abbasi F., Lamendola C., Liu A., Ariel D., Schaaf P., et al. : Benefits of liraglutide treatment in overweight and obese older individuals with prediabetes. Diabetes Care 36: 3276-3282 (2013)

50. Fujishima Y., Maeda N., Inoue K., Kashine S., Nishizawa H., Hirata A., et al.: Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes. Cardiovasc. Diabetol. 11: 107 (2012)